https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/04/cytokinetics-rallies-on-late-stage-myqorzo-data-strengthening-sales-outlook
Cytokinetics rallies on late-stage Myqorzo data, strengthening sales outlook | S&P Global
Cytokinetics' (NASDAQ: CYTK) shares surged after positive Phase 3 results for Myqorzo in treating nHCM, expanding its potential beyond oHCM. Analysts project...
https://www.goodrx.com/myqorzo/what-is
What is Myqorzo? - GoodRx
Learn about Myqorzo, dosing, proper use and what to know before beginning treatment
what ismyqorzogoodrx
https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-myqorzo
Drug Trials Snapshots: MYQORZO | FDA
MYQORZO is a cardiac myosin inhibitor used for treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional...
drug trials snapshotsmyqorzofda